Literature DB >> 21395651

Developmental variations in metabolic capacity of flavin-containing mono-oxygenase 3 in childhood.

Makiko Shimizu1, Travis Denton, Marie Kozono, John R Cashman, J Steven Leeder, Hiroshi Yamazaki.   

Abstract

AIM: The aim of this study was to investigate intra- and inter-individual variations of functional metabolic capacity of flavin-containing mono-oxygenase (FMO) during childhood using trimethylamine N-oxygenation as a probe reaction.
METHODS: Trimethylamine N-oxygenation functional activity and presence of FMO1 (fetal form), FMO3 (adult form), and FMO5 (endogenous form) were immunochemically determined and compared in human liver microsomes obtained from children at various ages. As a control, the same parameters were studied with recombinant FMO1, FMO3 and FMO5 proteins as enzyme sources. Developmental variation in functional metabolic capacity of FMO was estimated by measuring urinary trimethylamine and its N-oxide in several individuals at different ages and in a group of 77 subjects in childhood.
RESULTS: There was a significant correlation between trimethylamine N-oxygenation functional activity and FMO3 expression levels in human liver microsomes (r= 0.71, P < 0.05, n= 9). Trimethylamine N-oxygenation was catalyzed largely by FMO3 and not by FMO1 or FMO5. On the basis of analysis of intra-individual observations and collective urine samples under daily dietary conditions it was possible that neonates or infants harbouring at least one non-inactive-allele of the FMO3 gene could have developmental FMO3 metabolic capacity in childhood.
CONCLUSIONS: Developmental variations in functional metabolic capacity of FMO3 in childhood were shown both on the basis of in vivo phenotyping tests and in in vitro liver microsomal determinations.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21395651      PMCID: PMC3080647          DOI: 10.1111/j.1365-2125.2010.03876.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  A mutation in the flavin-containing monooxygenase 3 gene and its effects on catalytic activity for N-oxidation of trimethylamine in vitro.

Authors:  Megumi Kubota; Yoko Nakamoto; Kazuo Nakayama; Pailin Ujjin; Soisungwan Satarug; Taisei Mushiroda; Tsuyoshi Yokoi; Masato Funayama; Tetsuya Kamataki
Journal:  Drug Metab Pharmacokinet       Date:  2002       Impact factor: 3.614

2.  Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression.

Authors:  Sevasti B Koukouritaki; Pippa Simpson; Catherine K Yeung; Allan E Rettie; Ronald N Hines
Journal:  Pediatr Res       Date:  2002-02       Impact factor: 3.756

3.  Stop codon mutations in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population.

Authors:  Hiroshi Yamazaki; Haruka Fujita; Takaaki Gunji; Jun Zhang; Tetsuya Kamataki; John R Cashman; Makiko Shimizu
Journal:  Mol Genet Metab       Date:  2006-09-25       Impact factor: 4.797

4.  Ontogeny of dextromethorphan O- and N-demethylation in the first year of life.

Authors:  M J Blake; A Gaedigk; R E Pearce; L R Bomgaars; M L Christensen; C Stowe; L P James; J T Wilson; G L Kearns; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2007-02-14       Impact factor: 6.875

5.  Missense and nonsense mutations of the flavin-containing monooxygenase 3 gene in a Japanese cohort.

Authors:  Makiko Shimizu; Sachiko Tomioka; Norie Murayama; Hiroshi Yamazaki
Journal:  Drug Metab Pharmacokinet       Date:  2007-02-25       Impact factor: 3.614

6.  Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: correlation with hepatic transcription factors.

Authors:  Satomi Nagashima; Makiko Shimizu; Hiroshi Yano; Norie Murayama; Toshio Kumai; Shinichi Kobayashi; F Peter Guengerich; Hiroshi Yamazaki
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

7.  Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies.

Authors:  Virginie Lattard; Jun Zhang; Quyen Tran; Bjarte Furnes; Daniel Schlenk; John R Cashman
Journal:  Drug Metab Dispos       Date:  2003-07       Impact factor: 3.922

8.  Alternative processing events in human FMO genes.

Authors:  Virginie Lattard; Jun Zhang; John R Cashman
Journal:  Mol Pharmacol       Date:  2004-06       Impact factor: 4.436

9.  Genetic polymorphism of the flavin-containing monooxygenase 3 (FMO3) associated with trimethylaminuria (fish odor syndrome): observations from Japanese patients.

Authors:  Hiroshi Yamazaki; Makiko Shimizu
Journal:  Curr Drug Metab       Date:  2007-06       Impact factor: 3.731

10.  Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients.

Authors:  Hiroshi Yamazaki; Masaki Fujieda; Masahiro Togashi; Tetsuya Saito; George Preti; John R Cashman; Tetsuya Kamataki
Journal:  Life Sci       Date:  2004-04-16       Impact factor: 5.037

View more
  5 in total

1.  Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population.

Authors:  Makiko Shimizu; Charles K Allerston; Elizabeth A Shephard; Hiroshi Yamazaki; Ian R Phillips
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

Review 2.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

3.  Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver.

Authors:  Meijuan Xu; Deepak Kumar Bhatt; Catherine K Yeung; Katrina G Claw; Amarjit S Chaudhry; Andrea Gaedigk; Robin E Pearce; Ulrich Broeckel; Roger Gaedigk; Deborah A Nickerson; Erin Schuetz; Allan E Rettie; J Steven Leeder; Kenneth E Thummel; Bhagwat Prasad
Journal:  J Pharmacol Exp Ther       Date:  2017-08-17       Impact factor: 4.030

4.  Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy.

Authors:  Yumi Cleary; Michael Gertz; Paul Grimsey; Andreas Günther; Katja Heinig; Kayode Ogungbenro; Leon Aarons; Aleksandra Galetin; Heidemarie Kletzl
Journal:  Clin Pharmacol Ther       Date:  2021-09-01       Impact factor: 6.903

5.  Fish odor syndrome (trimethylaminuria) supporting the possible FMO3 down expression in childhood: a case report.

Authors:  Rosalia D'Angelo; Concetta Scimone; Teresa Esposito; Daniele Bruschetta; Carmela Rinaldi; Alessia Ruggeri; Antonina Sidoti
Journal:  J Med Case Rep       Date:  2014-10-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.